This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Privacy & Cookies policy
We love what we do and we are extremely motivated to work and deliver results. We have fun at work.
We are an open-minded company that is fully committed to open-discussion and out-of-the-box thinking to deliver innovative solutions to partners and customers.
We like to set ambitious goals, strive and achieve them.
We base our strategy on the quality of our solutions. We believe it’s best to do one thing really well than many things just well.
We strongly believe that human relations are crucial for an organization’s success. Hence, we enforce working with honesty, respect and integrity inside the company and with our collaborators and partners.
We recognize collaboration (and cross-discipline collaboration specially) as the appropriate mechanism to build solutions with greater impact. As a result, we are a company that is always looking for win-win collaborations and partnerships with organizations that share our mission and values.
CEO & Co-founder
CSO & Co-founder
CTO & Co-founder
CDBO
Senior Researcher
Business Developer Manager
Business Developer Manager
Business Advisor
Senior Researcher
Senior Engineer
Software Developer
Research intern
Scientific Advisor
Principal Scientist
Intern Software Engineer
Principal Scientist
Scientific Advisor
Have you studied computer science, computer engineering, biofinformatics, computational chemistry or medicinal chemistry?
Are you willing to work in an innovative software company?
Do you enjoy team working, innovation and challenging the status quo?
Are you looking for an industrial PhD degree on computer science or computational chemistry?
Send us your CV and a couple of references to hr[@]pharmacelera.com and join us!
Open positions
Computational Chemist – Barcelona. More information here.
Enric holds a PhD in Computer Engineering from Universitat Politècnica de Catalunya (UPC) and an Executive General Management Program degree from IESE Business School. Enric was a research visitor at the University of Illinois at Urbana Champaign and he worked for 10 years at Intel, where he led international teams from Israel, Germany, the United States and Spain in the fields of High-Performance Computing and Hardware/Software co-design. Enric is a co-author in 25 scientific publications and 20 filed patents and he was co-director of 3 PhD theses. Enric is co-founder and CEO of Pharmacelera.
Javier is a full-time professor at the University of Barcelona (UB), where he leads the Computational Biology and Drug Design (CBDD) research group, and he has a broad expertise in computational chemistry, medicinal chemistry and Computer-Aided Drug Design software. Javier has authored more than 400 publications that have been referenced more than 15,000 times, has an h-index of 72 based on Google Scholar and accumulates 12% of the official references of MOPAC (the open-source QM package).
Enric holds a PhD in Computer Engineering from Universitat Politècnica de Catalunya (UPC), where he obtained the UPC Award for Outstanding PhD Thesis. Enric was a research visitor at the University of California at San Diego. He is a co-founder of Pharmacelera and leads the Research & Development efforts. Prior to that, he worked at Intel in machine learning and hardware acceleration. Enric is a co-author in 14 scientific publications and 17 patents and has been co-director of 1 PhD thesis.
Greta holds a Business degree form Univeristat de Barcelona and Financial Management and Controlling postgraduate courses from UPF Barcelona School of Management. Greta accumulates more than 10 years of experience in finance management positions, focusing the last 6 years in Biotech and SaaS companies.
Rémy has over 30 years of experience in Sales and Business Development across various industries. He has experience in positioning and selling Computational Chemistry Medicinal Chemistry, ADME, Tox, Biology, Scale-up chemistry products and services. His areas of expertise include Providing effective sales techniques for Products & Services; Developing sales strategies; Nurturing and developing collaborative projects; Scientific Support to sales organisations; Transversal interaction with Product Marketing and R&D teams; Interaction with various customers (researchers from the pharma, biotech, academic and government teams) and Team Management.
He has published several articles in Computational Chemistry, and has co-edited two books (pharmacophores, data mining).
Prior to joining Pharmacelera, Rémy was associated with Jubilant Biosys as Senior Director Business Development for Discovery Services in Europe. Prior to Jubilant Biosys, he was associated with companies like Sai Life Sciences, BioAscent Discovery Ltd, Prestwick Chemicals, Thomson Reuters, Accelrys, etc.
He holds a Pharmacy degree and a Ph.D (Medicinal Chemistry) from Louis Pasteur University, Strasbourg, France.
Cynthia “Cindy” Tingle, PhD, is an organic chemist with postdoctoral research experience in organic synthesis, structural studies (X-ray and molecular modeling), and asymmetric catalysis, with publications in leading journals including Journal of the American Chemical Society and Journal of Organic Chemistry. Over the past 25 years, she has built a career at the intersection of science and technology, spanning AI/ML-enabled drug discovery, SaaS and cloud-scale data infrastructure, and scientific informatics solutions such as protein structure prediction, computational modeling, cheminformatics, and digital R&D platforms. She has held senior leadership and commercial roles leadership roles across business development, sales, customer success, operations, and consulting at organizations including PerkinElmer, CambridgeSoft, CAS, ChemAxon, Optibrium, and multiple AI-driven startups, leading global go-to-market strategies and driving digital transformation across pharmaceutical and biopharma R&D organizations.
Dr. Alessandro Monge has a background in science (quantum mechanics, statistical mechanics, molecular dynamics, and protein modeling) and over two decades of corporate and business development experience in the field of computation and AI for drug discovery. He is Managing Partner at Blue Dolphin and Strategic Business Advisor at Nanome, and has previously held senior management positions at Schrodinger, Iktos and TandemAI. Alessandro earned his Ph.D. in Theoretical Physics from The Rockefeller University and completed his postdoctoral work at Columbia University, jointly in the Departments of Chemistry and Biochemistry & Molecular Biophysics.
Tiziana obtained her PhD in Food Science and Technology with mention of excellence at the University of Parma (Italy) with a thesis focused on the application of computational techniques to food-related topics. During this period, she also contributed to the early development of QM-derived descriptors implemented in the PharmQSAR software. She accumulated 8 years of experience in computational chemistry and drug discovery working in academia. She was postdoctoral researcher in the Computational Biology and Drug Design research group at the University of Barcelona (Spain) and at the Spanish National Research Council (CIB-CSIC) in Madrid (Spain). She was also invited researcher at the University of Bristol (UK). She co-authored more than 25 peer-reviewed papers.
Carlos holds a Chemistry Degree from Universitat de Barcelona and MSc in Theoretical Chemistry and Computational Modelling from Universitat de Barcelona. At Pharmacelera, Carlos is developing a PhD in Computational Chemistry under the direction of Dr. Javier Vázquez and Prof. Francisco Javier Luque.
Javier holds a PhD in Computational Chemistry from Universitat de Barcelona (UB). His thesis was co-directed by Professor Javier Luque and Enric Herrero. Javier accumulates 6 years of experience in computational chemistry and molecular modelling and he has been an active contributor to the development of PharmScreen and PharmQSAR since he joined the company. Javier is co-author in 3 chemistry publications and 1 patent.
Albert holds a Computer Science degree from Universitat Politècnica de Catalunya (UPC), a MSc in Software Engineering from Universitat Oberta de Catalunya (UOC) and a MSc in Computational Engineering and Mathematics from Universitat Rovira i Virgili (URV). Albert accumulates more than 10 years of experience in software development and High-Performance Computing. Albert is co-author in 1 publication.
Marc holds a Higher-Level Training Cycle in telecommunications and is finishing a degree of Telematic Engineering from La Salle University. He brings more than six years of experience in Front-End and Back-End development in big Banking applications and e-commerce applications, those companies are among the most important Spanish companies.
Brian holds a Chemistry Degree from Universitat Autònoma de Barcelona and a MSc in Bioinformatics from Universitat Pompeu Fabra. He accumulates more than 2 years of experience in molecular simulations and computational chemistry. At Pharmacelera, Brian is developing his PhD in Computational Chemistry under the direction of Dr. Javier Vázquez and Prof. Jana Selent (IMIM). Brian is co-author in 5 scientific publications.
Carol holds a Ph.D. in Chemical Science and Technology from University of Balearic Islands (UIB), awarded as Outstanding PhD Thesis. During her PhD, she was a research visitor at University of Barcelona, Catalan Institute of Chemical Research (Tarragona) and Sheffield University. Carol performed several post-doctoral stays at Masaryk University (Czech Republic), University of Barcelona (UB) and University College London (UCL), in the latest as a Marie Curie Fellow. Now, she is a lecturer professor at the University of Barcelona (UB), joining the Computational Biology and Drug Design (CBDD) research group. She has experience in computational chemistry and drug discovery, with a high expertise in the use of a wide variety of computational techniques. Carol has authored more than 50 peer-reviewed publications that have been referenced more than 2,000 times, and has an h-index of 24 based on Google Scholar.
Aitor holds a Chemistry Degree and a MSc in Industrial Chemistry & Chemical Research, both from from Universitat Autònoma de Barcelona. He is developing his PhD in Biotechnology at the Universitat de Barcelona on the computational study of biomolecular interaction and design of drug-like compounds. Aitor collaborated in some projects for external companies performing quantum mechanics and molecular dynamics simulations. Aitor is author of two scientific publications and co-author in a third one.
Alex is a last-year student of Computer Science degree from the Universitat Politècnica de Catalunya (UPC). At Pharmacelera, Alex is developing his bachelor’s thesis and working in the backend.
Manel holds a PhD in Medicinal Chemistry and Molecular Modelling from Universitat de Barcelona (UB) and a Master Degree in Organic Chemistry from the same university. Manel accumulates more than 25 years of industrial experience in the fields of molecular modelling, medicinal and organic chemistry and drug discovery. He worked for 22 years in Almirall and he is now the head of Computational Chemistry at AB Science. Manel is co-author in one patent and in 26 scientific publications.
Beth Tuerk is a Computational Chemist with 8+ years of experience applying both physics-based molecular modeling and data-science approaches to accelerate preclinical drug discovery. She holds a PhD in Pharmacy from the University of Vienna (Austria, Barbara Zdrazil Group) and an MBA from the University of St. Francis (Illinois, USA), combining her scientific background with business intelligence.
Beth has gained international experience across leading institutions and innovative TechBio companies, including Celeris Therapeutics (Austria/UK, Head of CADD), AI|ffinity (Czechia, Operations & Business Development Manager), Uppsala University (Sweden, postdoc in Peter Kasson Group), and the European Bioinformatics Institute (EMBL-EBI, UK, Research Intern). She is a (co)-author of 10 scientific publications. At Pharmacelera, Beth works as an Application Scientist.
Woody Sherman is Founder and Chief Innovation Officer at Psivant Therapeutics, where he provides vision for Psivant’s mission to design better therapeutics leveraging the QUAISAR platform. Woody brings over 20 years of industry experience and has published over 100 peer reviewed scientific publications that span a broad range of topics, including molecular dynamics (MD), quantum mechanics (QM), free energy simulations, protein design, machine learning, cheminformatics, and computer-aided drug design.
Prior to founding and serving as CEO at Psivant from 2022-2024, Dr. Sherman was Chief Computational Scientist at Roivant Sciences from 2021-2022. From 2017-2021, Woody served as Chief Scientific Officer at Silicon Therapeutics and from 2009-2017 he was Vice President and Global Head of Applications Science at Schrödinger, Inc.
Woody earned his Ph.D. in Physical Chemistry at Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts. His Bachelor of Science degree in Chemistry and Bachelor of Arts in Creative Studies are from the University of California at Santa Barbara.
Mariana holds a PhD in Chemistry from Universidad de Santiago de Chile and she later performed post-doc stays at the University of Durham and Universität Konstanz working on Quantum Mechanics. Mariana is an experienced multilingual and multicultural entrepreneur and manager in the software and scientific industries. She accumulates 25 years of experience in Marketing and Business Development in the Life and Materials Science sector in companies such as Accelrys (now DS Biovia), Perkin Elmer, Dotmatics and Collaborative Drug Discovery (CDD). She also serves as advisor and member of the board in several life science companies.
Albert holds a Pharmacy degree from Universitat de Barcelona (UB), an MBA from EADA Business School and a Stanford School of Business and ESADE Business School degree on Corporate Social Responsibility. Albert accumulates 18 years of experience in business development, technology transfer, marketing and entrepreneurship in the areas of biotechnology, medical devices, digital health and drug discovery in Barcelona and Silicon Valley. He has raised more than 10M euros in his different roles and has served as mentor and board member in more than 10 start-ups.
Joan holds a degree in Medicine from Universitat Autònoma de Barcelona (UAB), a Management Degree from IESE Business School, a Business and Finance degree from Harvard Business School and a master’s degree in Biomedicine, Biotechnology and EU Law from UNED. He currently is the Director of Innovation at Hospital Clínic and the Director of Strategy and Innovation at Barcelona Institute for Global Health (ISGlobal). Joan is an internationally recognized person in the healthcare and pharmaceutical sector, working for 10 years as Medical Director at Bayer and 11 years as Director at Novartis.
Venkat Reddy, PhD, is the CSO of General Inception as well as serving on the Board of both Tactile Therapeutics which he co-founded and Pharmacelera.
Prior to joining General Inception in February 2022, Venkat was the CEO/CSO at Macrophage Pharma Ltd, and was responsible for R&D strategy, operations and fundraising activities.
Venkat has a successful track record and extensive strategic and management experience from senior executive roles in both European and US biotech and pharma, including Glenmark Pharmaceuticals (SVP, Global Head of Translational Sciences) managing translational strategy for Glenmark’s innovative medicines portfolio, Pfizer (Senior Director, Strategic Alliances and Partnerships, Centers for Therapeutic Innovation), Sanofi (Senior Director, Head, Bio-Innovation France: Global Biotherapeutics) and Novartis (Group leader, GNF).
Venkat holds a PhD from the Ludwig-Maximilians Universität München, undertook post-doctoral studies in immunology and oncology at the Scripps Research Institute and a Masters in Biotechnology at Jawaharlal Nehru University.
Raf is a Partner at HERAN Partners, a specialist venture capital investor committed to creating transformative impact within the life sciences and healthcare industry. He first spent a decade in operational roles in the biotech sector, which he complements with a decade of investment experience. Raf holds an M.Sc. in Biochemistry and Biotechnology from KULeuven, Belgium and an MBA from Vlerick Business School, as well as postgraduate certificates from Guberna. Prior to joining HERAN, he spent more than 5 years at Korys, a large Belgain-based family office, focusing on life science investments. He was involved with several young innovative companies and served as a strategic advisor for European and US-based investment funds.
Ignacio Prieto holds a degree in Biomedical Engineering from the University of Navarra and an MBA in Biotechnology from the University of Barcelona. He also completed a Master’s degree in Financial Management and Controlling at EAE Business School. He brings more than six years of experience in Venture Capital as an Investmen Analys, with a strong focus on life sciences, biotechnology and technology transfer. He currently serves on the Board o Director of eight biotechnology companies, where he is actively involved in supporting their strategic development and growth. In addition, Ignacio has a research background in areas such as tissue engineering and cellular ageing.